Literature DB >> 2178092

Structure-function studies on neuropeptide Y and pancreatic polypeptide--evidence for two PP-fold receptors in vas deferens.

J C Jørgensen1, J Fuhlendorff, T W Schwartz.   

Abstract

The biological effects of neuropeptide Y (NPY), rat pancreatic polypeptide (rPP), hybrid analogs of NPY and PP, and C-terminal fragments of NPY were studied in the field-stimulated rat vas deferens model. The results were correlated with peptide binding experiments in Y1 and PP receptor assays on rat PC-12 cells and Y2 receptors on porcine hippocampal membranes. NPY and rPP inhibited the electrically induced contractions in the vas deferens with an IC50 of 25 and 22 nM respectively. However, in contrast to NPY, rPP could not totally block muscle activity. The inhibitory action of the long C-terminal fragment of NPY, NPY-(19-36) and NPY-(11-36), indicated that NPY acts through a Y2 receptor in the vas deferens. The structural basis for the differential recognition of NPY and PP by Y2 receptors and partly also by PP receptors, could be defined with hybrid analogs of PP and NPY. The analogs, [Ile31,Gln34]PP and [Leu31,Pro33]NPY reacted in the vas deferens preparation in accordance with their relative potency in the Y2 and PP receptor assays. [Ile31,Gln34]PP, which bound to the Y2 receptor like NPY, was also able to block the part of the contractile response which was resistant to rPP. It is concluded that in the vas deferens, PP-fold peptides act through two types of receptors: Y2 and PP, and that residues in the C-terminal part of the molecules determine the differential recognition of the peptides by these receptor types.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2178092     DOI: 10.1016/0014-2999(90)94065-6

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

Review 1.  Physiology of the vas deferens.

Authors:  W D Steers
Journal:  World J Urol       Date:  1994       Impact factor: 4.226

2.  Constitutive neuropeptide Y Y(4) receptor expression in human colonic adenocarcinoma cell lines.

Authors:  H M Cox; I R Tough; D W Zandvliet; N D Holliday
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

3.  Discrimination by benextramine between the NPY-Y1 receptor subtypes present in rabbit isolated vas deferens and saphenous vein.

Authors:  S Palea; M Corsi; J M Rimland; D G Trist
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

4.  Strong evolutionary conservation of neuropeptide Y: sequences of chicken, goldfish, and Torpedo marmorata DNA clones.

Authors:  A G Blomqvist; C Söderberg; I Lundell; R J Milner; D Larhammar
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

5.  The cloned rat pancreatic polypeptide receptor exhibits profound differences to the orthologous receptor.

Authors:  I Lundell; M A Statnick; D Johnson; D A Schober; P Starbäck; D R Gehlert; D Larhammar
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

6.  Failure of the putative neuropeptide Y antagonists, benextramine and PYX-2, to inhibit Y2 receptors in rat isolated prostatic vas deferens.

Authors:  S Palea; M Corsi; J M Rimland; D G Trist; E Ratti
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

7.  Functional effects and ligand binding of chimeric galanin-neuropeptide Y (NPY) peptides on NPY and galanin receptor types.

Authors:  U Kahl; U Langel; T Bartfai; L Grundemar
Journal:  Br J Pharmacol       Date:  1994-04       Impact factor: 8.739

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.